IP Library › Granted Patent US 11,396,650
Granted Patent B2
US 11,396,650 · App. 15/578,962 · Granted Jul 26, 2022

Nucleic acid complexes for screening barcoded compounds

Inventors: Wesley Philip Wong (Cambridge, MA); Clinton H. Hansen (Cambridge, MA)
Assignee: Children's Medical Center Corporation
C12N15/1065C12N15/11C12N15/111C12N15/115C40B40/08C12N2310/16C12N2310/34C12N2310/3517C12N2320/10C40B20/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,396,650
App. No.
15/578,962
Granted
Jul 26, 2022
Kind
B2
Abstract

The invention provides compositions comprising nucleic acid complexes for use in screening compounds based on their ability to modulate binding interactions, wherein the compounds are barcoded.

Claims (17)

1. A method comprising

providing a nucleic acid complex conjugated to

(1) a target,

(2) a candidate target-specific ligand comprising an mRNA-displayed nanobody and a nucleic acid barcode, and

(3) a decoy,

allowing the target to contact and bind to the candidate target-specific ligand in the presence of the decoy,

isolating the nucleic acid complex having the target bound to the candidate target-specific ligand, and

identifying the candidate target-specific ligand,

wherein the nucleic acid complex comprises a single-stranded scaffold nucleic acid hybridized to a plurality of single-stranded oligonucleotides, wherein a first single-stranded oligonucleotide is linked to the target, a second single-stranded oligonucleotide is linked to the candidate target-specific ligand, and a third single-stranded oligonucleotide is linked to the decoy, and

wherein the target and the decoy are structurally similar but not identical to each other.

2. The method of claim 1 , wherein the candidate target-specific ligand comprises an amine modification, optionally at its 3′ end.

3. The method of claim 1 , further comprising crosslinking the candidate target-specific ligand to the bound target prior to isolating.

4. The method of claim 1 , wherein the mRNA-displayed nanobody comprises a linker comprising a 3′ terminal puromycin and a deoxythymine nucleotide modified with a methyl-tetrazine.

5. The method of claim 4 , wherein the scaffold of the nucleic acid complex comprises a trans-cyclooctene modification.

6. The method of claim 5 , wherein the mRNA-displayed nanobody is attached to the nucleic acid complex through a bond formed by reaction between the methyl-tetrazine on the linker and the trans-cyclooctene modification on the scaffold.

7. The method of claim 1 , wherein the target and the decoy are members of a protein family.

8. The method of claim 1 , wherein the method is a drug screening method comprising a plurality of nucleic acid complexes each comprising an identical target and a different candidate target-specific ligand itself having a unique barcode.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2019
From: WONG, WESLEY PHILIP; HANSEN, CLINTON H.
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 049897/0406 →
Continuity (2)
Provisional Application 62169826 · Jun 2, 2015
Related Publication 20180135043A1 · May 17, 2018
Cited By (3)
US 12,331,349 US 12,571,802 US 12,692,491